IDC

(redirected from cardiomyopathy)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

IDC

See: Interest During Construction

Intangible Drilling Costs

Expenses a company has when it drills for oil or natural gas. Intangible drilling costs are sometimes convenient for a company's tax purposes because it can deduct intangible drilling costs in one year when the company perhaps found little or no oil from profits made in a different year when the company does find oil.

Interest During Construction

In project finance, the interest that accumulates on a loan that finances the construction of a building or development. The IDC is a cost for the project, though it is not always calculated as such. The IDC is calculated until the project begins to generate revenue, when the company financing the project begins to service its debts.
References in periodicals archive ?
It further states years of gender-based research has revealed that Takotsubo cardiomyopathy, was first described in 1990 in Japan and is almost exclusively discovered in women with more than 90 percent of reported cases in women aged 58 to 75.
Many studies have been carried out to discover the relationship between cardiomyopathy and T wave alternans7,8.
Other important cause of dilated cardiomyopathy like presentation in young child is anomalous origin left coronary artery from pulmonary artery.
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy.
Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy.
8] The diagnostic criteria for apical hypertrophic cardiomyopathy included demonstration of asymmetric hypertrophy, confined predominantly to the apex with an apical wall thickness > 15 mm and a ratio of maximal apical to posterior wall thickness > 1.
Some of the tests used to diagnose peripartum cardiomyopathy include the following: ECHO, ECG, chest X-Ray, BNP and cardiac MRI.
Dilated cardiomyopathy or DCM is the most common form of non-ischemic cardiomyopathy condition that involves decreased heart function due to an enlarged heart which cannot pump blood efficiently and can affect the lungs, liver, and other body systems.
The report provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy
CAPR) said the first patient has been dosed in a clinical trial testing a stem cell therapy for Duchenne muscular dystrophy-related cardiomyopathy.
CAP-1002, an allogeneic, cardiosphere-derived stemcell (CDC) therapy, is being tested in the HOPEDuchenne Phase1/2 clinical trial (Halt cardiomyOPathy progrEssion in Duchenne) at the Cincinnati Children's Hospital Medical Center and at Cedars-Sinai Heart Institute in Los Angeles, Calif.
As cardiomyopathy worsens, the heart becomes weaker.

Full browser ?